Amplifon files GN Hearing valuation. Amplifon stock stands at EUR 12.47 versus EUR 7.84 low

Published on 10/20/2026 at 10:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amplifon stock costs EUR 12.47 on October 20, 2026 versus a EUR 15.84 52-week high. The next report is due October 29, 2026, with market value at EUR 2.7 billion.

GN Hearing deal and key dates

Amplifon updated GN Hearing valuation documents on October 8, 2026.
First-half 2026 revenue reached EUR 1.19 billion, up 1.30 percent at constant exchange rates.
Amplifon stock traded at EUR 12.47 at 10:42 a.m. CEST at Lang & Schwarz on October 20, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte und kleinem Hörgerät auf Holztisch — Flatlay-Arrangement mit Aktienzertifikat und Hörgerät illustriert Investment in Amplifon S.p.A., ISIN IT0004056880, dem Hörgeräte-Marktführer, Illustration mit AI erstellt.

Amplifon (IT0004056880) was trading at EUR 12.47 at Lang & Schwarz on October 20, 2026 at 10:42 a.m. CEST, while the company advanced its GN Hearing transaction documentation. Amplifon Corporate updated an expert valuation opinion on October 8, 2026, referring to GN Hearing as of June 30, 2026. The document keeps the planned acquisition and its financing structure at the center of the investor discussion.

GN Hearing reshapes the investment case

The transaction would move Amplifon toward a vertically integrated hearing-care model. On March 16, 2026, the company announced the acquisition of GN Hearing at a value of EUR 2.3 billion on a cash-free and debt-free basis, according to Rankia.

The financing has a substantial equity component. On May 22, 2026, Amplifon placed 45.3 million new shares for EUR 453 million, while the transaction plan also provides for 56 million shares for GN Store Nord at closing, Rankia reported. That structure gives the October 29 meeting a direct relevance for dilution and deal execution.

What do the margins show?

Amplifon's operating trend improved in the first half of 2026. Capital.com reported revenue of EUR 1.19 billion, up 1.30 percent at constant exchange rates, with organic growth of 3.50 percent. Adjusted EBITDA reached EUR 298.00 million, up 3.60 percent, and the adjusted EBITDA margin rose to 25.10 percent.

The second quarter supplied the sharper comparison: organic growth reached 4.70 percent, while the adjusted EBITDA margin reached 25.80 percent. Management guidance for 2026 calls for organic growth above 3.00 percent and an adjusted EBITDA margin increase of about 100 basis points, as reported by Capital.com.

Three milestones frame the deal

On March 16, 2026, Amplifon announced the EUR 2.3 billion GN Hearing acquisition. On May 22, 2026, it completed the EUR 453 million placement of 45.3 million new shares. On October 8, 2026, its expert opinion on GN Hearing used June 30, 2026 as the reference date.

Two dates set the next test

Amplifon Corporate scheduled the extraordinary and ordinary shareholders meeting for October 29, 2026. The third-quarter and nine-month results are also due on October 29, 2026, making that date the next combined operating and transaction checkpoint.

Stock remains below its yearly high

Amplifon stock was trading at EUR 12.47 at Lang & Schwarz on October 20, 2026 at 10:42 a.m. CEST. The 52-week range was EUR 7.84 to EUR 15.84, and market capitalization stood at EUR 2.7 billion. The stock is listed on Euronext Milan under ticker AMP and is a FTSE MIB constituent.

The further course of trading is shown by the continuously updated real-time quote of Amplifon stock.